Page 30 - BH-3-1
P. 30

Brain & Heart                                                                Cardioneuroablation for VMB




            Table 1. General characteristics and quality assessments of the included studies
            Study          Year   Design     Region   Number of   Indications  Locations of   Follow-up   Quality of study
                                                       patients            targeted GPs  (months)  (NOS score)
            Pachon et al. 6  2005  retrospective  Brazil  20     SND, AVB  RA/LA         9.2±4.1       6
            Zhao et al. 12  2015  retrospective  China   11      SB        RA/LA        18.4±6.2       6
            Aksu et al. 13  2016  prospective  Turkey    14      SND, AVB  RA/LA        10.9±3.3       7
            Qin et al. 16  2017   prospective  China     62      SB        RA/LA          12           8
            Debruyne et al. 19  2018  prospective  Belgium  8    SND       RA             12           6
            Güler et al. 32  2020  retrospective  Turkey  11     SND, AVB  RA/LA       52 (28 – 56)    7
            Lu et al. 33   2020   retrospective  China   13      SND, AVB  RA/LA        13.0±5.9       7
            Aksu et al. 24  2021  prospective  Turkey    31      AVB       RA/LA           -           8
            Aksu et al. 34  2021  retrospective  Turkey  19      SND, AVB  RA/LA        14.9±17        7
            Debruyne et al. 25  2021  prospective  Belgium  19   SND       RA             12           7
            Mesquita et al. 35  2021  prospective  Portugal  13  SND, AVB  RA/LA        6.5±23.4       6
            Aksu et al. 26  2022  prospective  Turkey    13      SND, AVB  RA/LA         8.0±3         7
            Chen et al. 36  2022  retrospective  China    6      SND       RA/LA           6           6
            Piotrowski et al. 27  2022  prospective  Poland  25  SND, AVB  RA/LA         10±3          7
            Rivarola et al. 37  2023  prospective  Brazil  36    SND, AVB  RA/LA        52.1±35.2      8
            Song et al. 38  2023  prospective  China     73      SB        RA/LA        27.2±17.4      8
            Wileczek et al. 28  2023  retrospective  Poland  178  SND, AVB  RA/LA         23.7         7
            Choi et al. 29  2024  retrospective  USA      6      SND, AVB  RA/LA          7.9          6
            Han et al. 39  2024   prospective  China     60      SND       LA             12           8
            Abbreviations: SND: Sinus node dysfunction; AVB: Atrioventricular block; SB: Sinus bradycardia; RA: Right atrium; LA: Left atrium;
            GPs: Ganglionated plexi; NOS: Newcastle–Ottawa Scale.



























            Figure 4. Forest plot of freedom from bradyarrhythmia-related symptoms. At the end of follow-up, 94.3% of patients (95% confidence interval: 90.9 – 97.7%,
            I² = 59%) were free from bradyarrhythmia-related symptoms.

            required  pacemaker  implantation  after  the  procedure.   3.2.3. Procedure-related complications
            The sensitivity analysis indicated that no individual study   The incidence of procedure-related complications was
            significantly altered the overall results.         analyzed in 294 patients from 7 studies using a common-



            Volume 3 Issue 1 (2025)                         5                                doi: 10.36922/bh.4824
   25   26   27   28   29   30   31   32   33   34   35